Pharma BD Deal Intelligence
BMS pivot followed Onglyza's failure to show CV superiority in SAVOR-TIMI-53 and Farxiga's prior FDA delay; deal lets BMS 'move to a more simplified operating…
AstraZeneca completed the acquisition of BMS's share of the global diabetes alliance on February 1, 2014, taking sole IP and global rights to Onglyza,…
Citi's Andrew Baum described the transaction as 'win-win for both parties' — BMS could focus on high-cost low-volume immuno-oncology while AZ committed more…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca acquired BMS's interests in the BMS-AZ diabetes alliance for $2.7B upfront plus up to $1.4B in regulatory/launch/sales milestones plus royalty payments through 2025 plus up to $225M asset-transfer payments.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Bristol-Myers Squibb diabetes alliance assets (this deal) | 2013 | $4.3B | 68 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Metabolic deals